The corporate will proceed to put money into each its generic and modern merchandise pipeline
Sun Pharmaceutical Industries Restricted expects its analysis spending to be about 6 to 7 per cent of gross sales for the monetary yr 2027, Dilip Shanghvi, Sun Pharma’s founder and Govt Chairman mentioned, after the corporate had introduced its monetary efficiency for the yr ended March 31, 2026.
The corporate will proceed to put money into each its generic and modern merchandise pipeline, he instructed analysts, including that within the yr underneath overview about 36 per cent of the spending was on modern merchandise.
On the $11.75 billion deal to accumulate Organon, that was introduced final month, Shanghvi mentioned, “we’ve got set up an integration administration workplace and have initiated actions for day one preparedness. The regulatory filings in varied markets is in progress. We count on the acquisition to be accomplished in Q4 FY27.”
Monetary efficiency
Earlier within the day, Sun Pharma had introduced particulars of its monetary efficiency and the corporate mentioned it clocked a 26.2 per cent progress in net profit, at ₹2,714 crore, for the fourth quarter ended March 31, 2026. The drugmaker’s gross sales for the fourth quarter stood at ₹14,559 crore, up 13.6 per cent. Its international modern medicines (previously specialty medicines) gross sales was $354 million. This was up 20.1 per cent and accounted for 22.2 per cent of gross sales, it mentioned.
Sun’s R&D funding for the quarter underneath overview was ₹975 crore, 6.7 per cent of gross sales. For your complete yr, the spending stood at ₹3,554 crore, 6.1 per cent of gross sales.
Kirti Ganorkar, Sun Managing Director, mentioned, “our full-year efficiency displays a number of vital achievements. Sun’s 0.3 proportion level acquire within the India market is our highest acquire because the Ranbaxy acquisition. Our US Revolutionary medicines enterprise has surpassed $1 billion in revenues, whereas ex-US modern medicines continues to show robust progress momentum. The lately introduced Organon acquisition is anticipated to additional speed up Sun’s transformation into a number one international pharmaceutical firm.”
For the yr ended March 31, 2026 (FY26), the corporate’s net profit was up 5 p.c, at $11,479 crore. Its gross sales stood at $58,220 crore, up 11.9 per cent. Its international modern medicines gross sales clocked $ 1,420 million, up 16.4 per cent and accounting for 20.7 per cent of gross sales, each ex-milestone, the corporate mentioned.
The corporate’s board of administrators proposed a remaining dividend of ₹5 per share for the yr FY26. That is along with the interim dividend of ₹11 per share paid in FY26, taking the entire dividend for FY26 to ₹16 per share, identical as FY25, the corporate mentioned.
Printed on Could 22, 2026
Source link
#Sun #Pharma #net #profit #cent
